NVRO - Nevro Corp.

NYSE - NYSE Delayed Price. Currency in USD
44.04
+2.24 (+5.36%)
At close: 4:02PM EST

44.04 0.00 (0.00%)
After hours: 4:49PM EST

Stock chart is not supported by your current browser
Previous Close41.80
Open41.53
Bid0.00 x 900
Ask47.31 x 800
Day's Range41.34 - 44.86
52 Week Range34.75 - 94.34
Volume682,419
Avg. Volume751,448
Market Cap1.328B
Beta (3Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.91
Trade prices are not sourced from all markets
  • Markit12 hours ago

    See what the IHS Markit Score report has to say about Nevro Corp.

    # Nevro Corp ### NYSE:NVRO View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.36 billion over the last one-month into ETFs that hold NVRO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire7 days ago

    Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Nevro Corp. Investors (NVRO)

    LOS ANGELES, Jan. 10, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Nevro Corp. (NYSE: NVRO).

  • Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
    PR Newswire10 days ago

    Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

    REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. The company announced that preliminary unaudited fourth quarter 2018 worldwide revenue is expected to be in the range of $107.6 to $108.1 million, compared to $98.0 million in the prior year quarter.  Preliminary unaudited U.S. revenue for the fourth quarter of 2018 is expected to be in the range of $91.5 to $91.8 million, compared to $81.1 million in the prior year quarter.  Preliminary unaudited international revenue for the fourth quarter of 2018 is expected to be in the range of $16.1 to $16.3 million, compared to $16.9 million in the prior year quarter.

  • Nevro to Present at the 37th Annual J.P. Morgan Healthcare Conference
    PR Newswire28 days ago

    Nevro to Present at the 37th Annual J.P. Morgan Healthcare Conference

    REDWOOD CITY, Calif. , Dec. 20, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...

  • Simply Wall St.last month

    Does Nevro Corp.’s (NYSE:NVRO) Past Performance Indicate A Weaker Future?

    When Nevro Corp. (NYSE:NVRO) announced its most recent earnings (30 September 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers Read More...

  • Markitlast month

    See what the IHS Markit Score report has to say about Nevro Corp.

    # Nevro Corp ### NYSE:NVRO Score: Positive (71) 3 days at current score. Upgraded from Neutral on December 11th 2018 View full report here! ## Summary * This company ranked positively in all 3 IHS Markit categories and the Healthcare sector * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding NVRO are favorable, with net inflows of $2.94 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Nevro Corp (NVRO) Going to Burn These Hedge Funds?
    Insider Monkeylast month

    Is Nevro Corp (NVRO) Going to Burn These Hedge Funds?

    Does Nevro Corp (NYSE:NVRO) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]

  • See what the IHS Markit Score report has to say about Nevro Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Nevro Corp.

    Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding NVRO are favorable, with net inflows of $2.70 billion.

  • See what the IHS Markit Score report has to say about Nevro Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Nevro Corp.

    Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold NVRO had net inflows of $2.16 billion over the last one-month.

  • Spinal-cord stimulators mean big business for device makers
    Associated Press2 months ago

    Spinal-cord stimulators mean big business for device makers

    Few medical devices hold as much potential for explosive growth as spinal-cord stimulators , especially in the United States, where they are being pushed as the answer to the country's opioid epidemic. The global market for spinal-cord stimulators has grown from $300 million in 2001 to nearly $2 billion in 2017, according to an estimate by Nevro, a Redwood City, California, company that manufactures the devices. The financial services firm Canaccord Genuity Inc. has estimated that the market could approach $20 billion, saying the current market penetration represents only about 7 percent of potential customers.

  • See what the IHS Markit Score report has to say about Nevro Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Nevro Corp.

    Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold NVRO had net inflows of $2.42 billion over the last one-month.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NVRO earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 Nevro Corp Earnings Call

  • Business Wire2 months ago

    Robbins Arroyo LLP: Officers and Directors of Nevro Corp. (NVRO) Breached Their Fiduciary Duties According to Shareholder Lawsuit

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nevro Corp. (NVRO) have filed a shareholder lawsuit against the company's officers and directors for breaches of their fiduciary duties from January 8, 2016 through the present. Nevro's principal products are its HF10 therapies delivered by its Senza I and Senza II spinal cord stimulation systems. According to the complaint, Nevro is engaged in several patent disputes with Boston Scientific Corp. relating to Nevro's HF10 therapies and the Senza systems.

  • GlobeNewswire2 months ago

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Nevro Corporation (NVRO) and Encourages NVRO Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Nevro Corporation (NVRO). If you are a long term stockholder of Nevro, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

  • Here's Why Nevro Corp. Shares Fell 16.9% Today
    Motley Fool2 months ago

    Here's Why Nevro Corp. Shares Fell 16.9% Today

    The company's third-quarter earnings and guidance for slowing unit sales are causing shares to slide.

  • MarketWatch2 months ago

    Nevro's stock tumbles toward 3-year low after downbeat outlook prompts J.P. Morgan downgrade

    Shares of Nevro Corp. plunged 15% toward a 3-year low in morning trade Tuesday, after the maker of the Senza spinal cord stimulation system for the treatment of chronic pain reported a wider-than-expected third-quarter loss, according to FactSet, although revenue topped expectations. The company also said on the post-earnings conference call late Monday that unit sales data suggests U.S. growth rates have "slowed significantly" from 20% in 2017 to 5% to 8% in the third quarter, according to a transcript provided by FactSet. That prompted J.P. Morgan analyst Robert Marcus to downgraded the stock to neutral from overweight and slash his price target to $45 from $77, citing the "notable stepdown" in growth expectations. Among other analyst moves, Leerink's Danielle Antalffy cut her price target to $65 from $78 and Canaccord Genuity's Jason Mills dropped his target to $63 from $80. The stock was on track for the lowest close since Oct. 23, 2015. It has plummeted 38% over the past three months, while the S&P 500 has slipped 3.5%.

  • Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

    Nevro (NVRO) delivered earnings and revenue surprises of -23.33% and 2.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Nevro: 3Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 37 cents. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...

  • Nevro Reports Third Quarter 2018 Financial Results
    PR Newswire2 months ago

    Nevro Reports Third Quarter 2018 Financial Results

    REDWOOD CITY, Calif. , Nov. 5, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today ...

  • Simply Wall St.2 months ago

    What Investors Should Know About Nevro Corp’s (NYSE:NVRO) Financial Strength

    Investors are always looking for growth in small-cap stocks like Nevro Corp (NYSE:NVRO), with a market cap of US$1.4b. However, an important fact which most ignore is: how financially healthy Read More...

  • PR Newswire3 months ago

    Lifshitz & Miller LLP Announces Investigation of Corium International, Inc., Dragon Victory International Limited, Honeywell International Inc., Hortonworks, Inc., Idaho Independent Bank, L3 Technologies, Inc., MBT Financial Corp., Nevro Corp., and Ormat Technologies, Inc.

    NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Corium International, Inc. (CORI) Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties in connection with the sale of CORI to Gurnet ...

  • Nevro (NVRO) Q3 Earnings Preview: What to Look Out For
    Zacks3 months ago

    Nevro (NVRO) Q3 Earnings Preview: What to Look Out For

    Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • See what the IHS Markit Score report has to say about Nevro Corp.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Nevro Corp.

    Short interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $1.22 billion over the last one-month into ETFs that hold NVRO are not among the highest of the last year and have been slowing.

  • Business Wire3 months ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nevro Corporation to Contact The Firm

    Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nevro Corporation (“Nevro” or the “Company”) (NVRO) of the October 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Nevro stock or options between January 8, 2018 and July 12, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/NVRO. The case, Oklahoma Police Pension and Retirement System v. Nevro Corporation et al., No. 18-cv-05181 was filed on August 23, 2018, and has been assigned to Judge Yvonne Gonzalez Rogers.